デンドリット細胞生物学は,臨床応用へと進化しています.

Same author

Distinguishing human peripheral blood CD16<sup>+</sup> myeloid cells based on phenotypic characteristics.

Journal of leukocyte biology·2019

Same author

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.

Molecular oncology·2019

Same author

CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Frontiers in immunology·2019

Same author

Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.

PloS one·2019

Same author

The cell surface phenotype of human dendritic cells.

Seminars in cell & developmental biology·2018

Same author

Dendritic cells as cancer therapeutics.

Seminars in cell & developmental biology·2018

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026

Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026

関連する実験動画

デンドリット細胞生物学は,臨床応用へと進化しています.

関連する概念動画

Distinguishing human peripheral blood CD16<sup>+</sup> myeloid cells based on phenotypic characteristics.

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.

CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.

The cell surface phenotype of human dendritic cells.

Dendritic cells as cancer therapeutics.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

関連する実験動画

デンドリット細胞生物学は,臨床応用へと進化しています.

関連する概念動画

関連記事

Distinguishing human peripheral blood CD16<sup>+</sup> myeloid cells based on phenotypic characteristics.

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.

CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.

The cell surface phenotype of human dendritic cells.

Dendritic cells as cancer therapeutics.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.